炎症性肠病与前列腺癌风险
单中心回顾性匹配队列研究(1996-2017)纳入1033例IBD男性与9306例对照,比较前列腺癌发病率。IBD组10年前列腺癌累积发病率为4.4%,对照组为0.65%(HR 4.84,P<0.001);临床显著前列腺癌(Gleason≥2)分别为2.4%和0.42%(HR 4.04,P<0.001)。约60岁后IBD患者PSA值更高。
要点
- IBD男性前列腺癌10年累积发病率4.4%,显著高于匹配对照的0.65%。
- 临床显著前列腺癌(Gleason≥2)在IBD组为2.4%,对照组为0.42%。
- 约60岁后IBD患者PSA值更高,提示需关注该人群筛查。
核心结论
- 与年龄和种族匹配的对照相比,IBD男性临床显著前列腺癌发生率更高。
研究设计与样本
- 单中心回顾性匹配队列研究,1996-2017年,IBD男性1033例按1:9随机匹配无IBD男性9306例,所有患者至少接受一次PSA筛查。
主要发现
- 约60岁后IBD患者PSA值更高(年龄与患者组固定效应交互作用P=0.004)。
临床怎么用
- 对IBD男性,尤其60岁以上者,应关注前列腺癌筛查与PSA监测。
局限性
- 回顾性分析设计。
- 缺乏外部有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are limited data examining the risk of prostate cancer (PCa) in patients with inflammatory bowel disease (IBD). OBJECTIVE: To compare the incidence of PCa between men with and those without IBD. DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective, matched-cohort study involving a single academic medical center and conducted from 1996 to 2017. Male patients with IBD (cases=1033) were randomly matched 1:9 by age and race to men without IBD (controls=9306). All patients had undergone at least one prostate-specific antigen (PSA) screening test. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Kaplan-Meier and multivariable Cox proportional hazard models, stratified by age and race, evaluated the relationship between IBD and the incidence of any PCa and clinically significant PCa (Gleason grade group ≥2). A mixed-effect regression model assessed the association of IBD with PSA level. RESULTS AND LIMITATIONS: PCa incidence at 10yr was 4.4% among men with IBD and 0.65% among controls (hazard ratio [HR] 4.84 [3.34-7.02] [3.19-6.69], p<0.001). Clinically significant PCa incidence at 10yr was 2.4% for men with IBD and 0.42% for controls (HR 4.04 [2.52-6.48], p<0.001). After approximately age 60, PSA values were higher among patients with IBD (fixed-effect interaction of age and patient group: p=0.004). Results are limited by the retrospective nature of the analysis and lack of external validity. CONCLUSIONS: Men with IBD had higher rates of clinically significant PCa when compared with age- and race-matched controls. PATIENT SUMMARY: This study of over 10000 men treated at a large medical center suggests that men with inflammatory bowel disease may be at a higher risk of prostate cancer than the general population.
引用
- Burns JA, Weiner AB, Catalona WJ, et al. Inflammatory Bowel Disease and the Risk of Prostate Cancer. Eur Urol. 2018. PMID: 30528221. doi:10.1016/j.eururo.2018.11.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。